L NanoMedicineAustria PINKComplex illnesses like cancer, cardiovascular diseases, multiple sclerosis, Alzheimer’s and Parkinson’s disease as well as different kinds of serious inflammatory or infectious diseases (e.g. HIV) have a tremendous negative impact, not only on the patient himself but also on the whole society and linked social and insurance systems. These diseases have been key topics in the broad field of biomedical research in the past decades on a global level, and large amounts of investigations and studies have been carried out. However, appropriate diagnosis, treatments as well as preventive methods still pose one of the biggest challenges that society faces.

Advanced nano- and biomaterials for medical applications that facilitate new methods and multidisciplinary approaches promise to tackle these challenges.
As one of the most promising KETs, nanotechnology facilitates major breakthroughs in different application sectors. Nanomedicine, the application of nanotechnology to health, raises high expectations for millions of patients for better, more efficient and affordable healthcare, and promises new solutions to improve medical treatments. Moreover, fundamental research in nanomedicine allows a better understanding of biological processes in the human body at molecular and nanometric level. Several areas of medical care are already benefiting from the advantages that nanotechnology can offer.
Bio- and nanomedicine opens up fascinating new chances for medical applications by offering novel methods for drug delivery systems, imaging techniques, diagnostic tools, etc. The diversity of these topics encourages interdisciplinary expertise and connects a variety of scientific fields. The use of smallest particles in the nanometer range enables new methods for improved treatment of numerous diseases. Through Austria`s excellent scientific expertise in these fields, it has also high economic potential.

In 2015, BioNanoNet founded the Austrian platform "NanoMedicine-Austria" to ensure Austria a leading position in this promising and economically highly interesting field. The aim of this platform is to bring together Austrian bio- and nanomedical experts into one platform in order to create appropriate structures to promote science and research and to strengthen the scientific and business location Austria sustainably.
Bundling of bio- and nanomedical expertise

At the first Austrian NanoMedicine Day on 5th of April 2016 at the Danube University Krems, 22 experts from all over Austria discussed and defined the topics to be dealt with in the coming years and the necessary framework conditions in research, education and technology transfer. The discussion about nanotechnologies applied to medicine to address medical needs focused on the topics (i) diagnostics and imaging, (ii) therapeutics and (iii) regenerative medicine. Interesting ideas were exchanged and views on possible future applications for the coming years were given. The results and central ideas will be further developed in upcoming activities.
We kindly invite you to become part of NanoMedicine-Austria contributing your relevant expertise in the platform; if you are interested, please contact office@nanomedicine-austria.at.
  • European Society for Nanomedicine (ESNAM)
The European Society for Nanomedicine is a society of individuals and bodies across Europe that focuses on the clinical application of nanomedicine and its implications for individuals and society. Through this focus, it complements a number of already existing European platforms, initiatives, and framework-programmes that see their main task in linking researchers and industry.
  • European Technology Platform Nanomedicine (ETPN)

The ETPN is an important European Technology Platform that contributes to the advancement nanomedicine in Europe.
BioNanoNet is member of the Executive Board of the ETPN and co-chair of the working group “Toxicology & Characterisation”, actively contributes to the establishment of the strategic research and innovation agenda of ETPN and helps  prepare call topics for future HORIZON 2020-calls (NMP, HEALTH, ICT).
BioNanoNet is coordinator of the Austrian national technology platform NanoMedicine-Austria. Further information: https://www.bnn.at/testseite/national-technology-platforms/nanomedicine-austria
Logo NWCD 2018


Precision Medicine for People – Smart Biomarkers, Nanotechnologies and more

Date: 31st of January, 2018, 10:45 – 16:00 Uhr
Location: Unfallkrankenhaus Lorenz Böhler, Donaueschingenstraße 13, A-1200 Vienna
BioNanoNet ForschungsGmbH, CBmed GmbH, and the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology organised the Nano World Cancer Day on 31st of January, 2018 at the Unfallkrankenhaus Lorenz Böhler. 
The Nano World Cancer Day is an event series held in parallel in different European countries to raise awareness about how nanomedical innovations help to fight cancer. The purpose of this event is to inform the wider public about latest findings in nanomedical research and applications in the oncological field.
Impressions of this event series from thel ast years can be obtained from www.nwcd.eu.
Press folder:
Presentations of the press meeting are available for download now:
Press Articles:
Press Release NWCD 2018:
Andreas Falk, MSc., CEO BioNanoNet ForschungsGmbH
andreas.falk@bnn.at - +43 699 155 266 01
Pictures from the NWCD 2018:
Vortragende Pressegespraech NWCD2018
from the left: Andreas Falk, MSc (BioNanoNet), Univ.-Prof. Dr. Heinz Redl (LBI Trauma), Mag. Alexander Pogàny (BMVIT), Univ.-Ass. DI Dr. Hannes Mikula (TU Wien), Univ.-Prof. Dr. Thomas Pieber (CBmed)
Vortragender Andras Falk BioNanoNet
Andreas Falk, MSc (BioNanoNet) über „NanoMedicine-Austria – österreichische Initiative im Zukunftsthema Nanomedizin“
 Vortragender Heinz Redl LBI Trauma
Univ.-Prof. Dr. Heinz Redl (LBI Trauma) spricht über „Nanoaspekte in der Regenerativen Medizin“
Vortragender Thomas Pieber CBmed
Univ. Prof. Dr. Thomas R. Pieber (CBmed) spricht über „Translationale Biomarkerforschung – Konzepte für die onkologische Forschung“
Vortragender HannesMikula TUWien
Univ.-Ass. DI Dr. Hannes Mikula (TU Wien) spricht über „Bio-rechtwinkelige Chemie in der Nanomedizin“
Diskussion Vortragende Pressegespraech
Diskussion Pressegespräch mit den Vortragenden (v.l.) Univ.-Prof. Dr. Heinz Redl (LBI Trauma), Univ.-Prof. Dr. Thomas Pieber (CBmed), Univ.-Ass. DI Dr. Hannes Mikula (TU Wien) und Mag. Alexander Pogàny (BMVIT)
Vortragende Symposium
Wissenschaftliches Symposium  mit (v.l.) Andreas Falk, Msc (BioNanoNet), DI Thomas Mohr (ScienceConsult DI Thomas Mohr KG), Dr. Gregory Vladimer (allcyte GmbH c/o CeMM), Priv.-Doz. Amin El-Heliebi, Ph.D. (Medizinische Universität Graz) und Univ.-Prof. Dr. Thomas Pieber (CBmed)

Mag.a pharm. Susanne Resch

Mobile:  +43 699 155 266 03


Andreas Portrait sw

Andreas Falk, MSc

Mobile: +43 699 155 266 01